Eupraxia Pharmaceuticals (EPRX) Interest Expenses (2023 - 2025)

Eupraxia Pharmaceuticals (EPRX) has 3 years of Interest Expenses data on file, last reported at $43.4 million in Q4 2025.

• On a quarterly basis, Interest Expenses rose 3492.85% year-over-year to $43.4 million in Q4 2025; TTM through Dec 2025 was $43.4 million, a 7084.89% increase from a year earlier, with the FY2025 full-year figure at $43.4 million, up 38.45% from the prior year.
• Interest Expenses for Q4 2025 stood at $43.4 million, up from $1.2 million in the prior quarter.
• Over the last five years, Interest Expenses for EPRX reached as high as $43.4 million in Q4 2025 and fell as low as -$321140.0 in Q1 2024.
• Historically, Interest Expenses has averaged $5.0 million across 3 years, with a median of -$281845.0 in 2024.
• Across the five-year window, Interest Expenses tumbled 42.08% in 2024 and jumped 3492.85% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $2.1 million in 2023, then sank by 42.08% to $1.2 million in 2024, then soared by 3492.85% to $43.4 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were $43.4 million in Q4 2025, $1.2 million in Q4 2024, and -$451.0 in Q3 2024.